Related Experiment Video
Updated: Mar 19, 2026
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Developments of Anticoagulants and New Agents with Anti-Coagulant Effects in Deep Vein Thrombosis
Yi-Ping Dang, Yun-Fei Chen, Yi-Qing Li
1Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Insights
New anticoagulants targeting Factor Xa show promise for preventing deep vein thrombosis (DVT) and pulmonary embolism (PE). These novel agents offer potential advantages over existing therapies, with ongoing research exploring botanical extracts and synthetic compounds for improved safety and efficacy.
Area of Science:
- Pharmacology
- Hematology
- Drug Discovery
Background:
- Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) are significant global health concerns, often treated with anticoagulants like Vitamin K antagonists (VKAs) and heparins.
- Existing anticoagulants carry risks, including hemorrhage, necessitating the development of safer and more effective alternatives.
- New Oral Anticoagulants (NOACs), including direct thrombin inhibitors (DTIs) and direct factor Xa inhibitors, offer advantages like rapid action and reduced monitoring, though challenges like cost and lack of antidotes remain.
Purpose of the Study:
- To review the current landscape of anticoagulant therapies for DVT and PE.
- To highlight the development and potential of novel anticoagulants, particularly those targeting Factor Xa.
- To explore emerging therapeutic strategies, including synthetic compounds and botanical extracts, for improved DVT prevention and treatment.
Main Methods:
- Literature review of existing anticoagulant therapies and emerging drug candidates.
- Analysis of the role of Factor Xa in coagulation and its potential as a therapeutic target.
- Examination of recent research on novel synthetic inhibitors and naturally derived anticoagulants.
Main Results:
- NOACs represent a significant advancement over traditional anticoagulants, offering improved pharmacokinetic profiles.
- Factor Xa inhibitors are a key focus for new drug development due to their critical role in the coagulation cascade.
- Emerging compounds, including DPC423, coumarin derivatives, phenyltriazolinones, and botanical extracts, demonstrate potent anticoagulant and anti-inflammatory properties.
Conclusions:
- Novel anticoagulants targeting Factor Xa hold significant potential for more effective and safer prevention of DVT and PE.
- Further research into synthetic and botanical agents may yield next-generation oral anticoagulants with enhanced therapeutic benefits.
- Addressing challenges such as antidote availability and cost will be crucial for the widespread clinical adoption of new anticoagulant therapies.
Abstract:
Deep Vein Thrombosis (DVT) has been known as a common medical problem all over the world. Thrombus traveling in blood vessels may lead to pulmonary embolism (PE), associated with high rates of mortality. Anticoagulant therapy is the mainstay treatment of DVT. Common anticoagulants, Vitamin K antagonists (VKAs), unfractionated heparin (UFH) and Low-molecular-weight heparin (LMWH) have been used in clinical application over decades, but can increase the risk of hemorrhage. Thereby, several new oral anticoagulants (NOACs) have been developed, which includes direct thrombin inhibitors (DTI) and direct factor Xa inhibitors. To be contrast with VKAs and UFH, NOACs have many advantages such as rapid offset action, few drug/food interactions and no need for routine coagulation monitoring, etc. Many NOACs are still being evaluated in Phase III clinical trials such as Betrixaban and Darexaban (YM150). However, NOACs still have problems to be solved such as lack of antidotes and laboratory monitoring, high drug costs, etc. Besides, several agents have already shown the potential to be new anticoagulants. Factor Xa play an important role in thrombin generation and coagulation pathway. Thus, the new compounds directly targeting on factor Xa for prevention DVT are highly anticipated. DPC423, a new series of 6-substituted coumarin derivatives and Phenyltriazolinones as potent factor Xa inhibitors have been recently reported. Recent studies revealed that agents extracted from botanicals not only have anti-coagulant effects but also possess other pharmacological activities such as anti-inflammation to alleviate the post-thrombotic syndromes. All the evidence above suggests that many new compounds might have great potential to be more effective and safe oral anticoagulants.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:30Venous Thrombosis I: Introduction
01:30Venous Thrombosis IV: Nursing Management